A double-blind, multi-site, placebo-controlled, parallel-group design to assess the efficacy, safety and dose-response characterisation of STS-01 for the treatment of alopecia areata
Latest Information Update: 02 Jul 2024
At a glance
- Drugs STS-01 (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- Acronyms SOT01
- Sponsors Soterios
Most Recent Events
- 10 Jun 2024 Top-line results presented in a SiSaf Media Release.
- 04 Jun 2024 Status changed from active, no longer recruiting to completed.
- 04 Jun 2024 Status changed from recruiting to active, no longer recruiting.